These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 3104890)
1. Protective effect of CR 1409 (cholecystokinin antagonist) on experimental pancreatitis in rats and mice. Makovec F; Bani M; Cereda R; Chistè R; Revel L; Rovati LC; Setnikar I; Rovati LA Peptides; 1986; 7(6):1159-64. PubMed ID: 3104890 [TBL] [Abstract][Full Text] [Related]
2. Effects of loxiglumide on experimental acute pancreatitis in comparison with gabexate mesilate. Kimura K; Tominaga K; Fujii M; Saito T; Kasai H Arzneimittelforschung; 1998 Jan; 48(1):65-9. PubMed ID: 9522035 [TBL] [Abstract][Full Text] [Related]
3. Effect of a new cholecystokinin receptor antagonist loxiglumide on acute pancreatitis in two experimental animal models. Tani S; Okabayashi Y; Nakamura T; Fujii M; Itoh H; Otsuki M Pancreas; 1990 May; 5(3):284-90. PubMed ID: 2343042 [TBL] [Abstract][Full Text] [Related]
4. Effect of a new cholecystokinin receptor antagonist CR 1392 on caerulein-induced acute pancreatitis in rats. Otsuki M; Tani S; Okabayshi Y; Nakamura T; Fujii M; Fujisawa T; Baba S; Itoh H Pancreas; 1989; 4(2):237-43. PubMed ID: 2474165 [TBL] [Abstract][Full Text] [Related]
6. Experimental acute pancreatitis induced by excessive doses of caerulein in rats; protective and therapeutic effects of trypsin inhibitor urinastatin and CCK receptor antagonist CR1392. Tani S Kobe J Med Sci; 1988 Apr; 34(2):93-112. PubMed ID: 3216603 [No Abstract] [Full Text] [Related]
7. Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis. Taniguchi H; Yomota E; Kume E; Shikano T; Endo T; Nagasaki M Jpn J Pharmacol; 1997 Feb; 73(2):105-12. PubMed ID: 9074944 [TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis. Niederau C; Liddle RA; Ferrell LD; Grendell JH J Clin Invest; 1986 Oct; 78(4):1056-63. PubMed ID: 2428840 [TBL] [Abstract][Full Text] [Related]
10. Cholecystokinin receptor antagonism by peptidergic and non-peptidergic agents in rat pancreas. Dembinski A; Jaworek J; Konturek PK; Konturek SJ; Warzecha Z J Physiol; 1989 Apr; 411():419-35. PubMed ID: 2614728 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Makovec F; Bani M; Cereda R; Chisté R; Pacini MA; Revel L; Rovati LA; Rovati LC; Setnikar I Arzneimittelforschung; 1987 Nov; 37(11):1265-8. PubMed ID: 3440035 [TBL] [Abstract][Full Text] [Related]
12. The effect of a cholecystokinin receptor antagonist lorglumid on the proteinase-antiproteinase balance in taurocholate acute experimental pancreatitis (AEP) in rats. Kosidło S; Rydzewska G; Gabryelewicz A Mater Med Pol; 1992; 24(4):223-6. PubMed ID: 1308047 [TBL] [Abstract][Full Text] [Related]
13. Effect of endogenous cholecystokinin on the course of acute pancreatitis in rats. Jia D; Yamamoto M; Otsuki M World J Gastroenterol; 2015 Jul; 21(25):7742-53. PubMed ID: 26167074 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic effects of loxiglumide on experimental acute pancreatitis using various models. Satake K; Kimura K; Saito T Digestion; 1999; 60 Suppl 1():64-8. PubMed ID: 10026435 [TBL] [Abstract][Full Text] [Related]
15. The anti-CCK effect of glutaramic acid derivatives in anesthetized and conscious rats. Takács T; Nagy I; Pap A; Varró V Pancreas; 1988; 3(4):465-70. PubMed ID: 3174609 [TBL] [Abstract][Full Text] [Related]
16. Antispasmodic activity on the gallbladder of the mouse of CR 1409 (lorglumide) a potent antagonist of peripheral CCK. Makovec F; Bani M; Cereda R; Chistè R; Pacini MA; Revel L; Rovati LC Pharmacol Res Commun; 1987 Jan; 19(1):41-51. PubMed ID: 3575382 [TBL] [Abstract][Full Text] [Related]
17. Modulation by CR-1409 (lorglumide), a cholecystokinin receptor antagonist, of trypsin inhibitor-enhanced growth of azaserine-induced putative preneoplastic lesions in rat pancreas. Douglas BR; Woutersen RA; Jansen JB; de Jong AJ; Rovati LC; Lamers CB Cancer Res; 1989 May; 49(9):2438-41. PubMed ID: 2706631 [TBL] [Abstract][Full Text] [Related]
18. Pancreatic growth: interaction of exogenous cholecystokinin, a protease inhibitor, and a cholecystokinin receptor antagonist in mice. Niederau C; Liddle RA; Williams JA; Grendell JH Gut; 1987; 28 Suppl(Suppl):63-9. PubMed ID: 2446964 [TBL] [Abstract][Full Text] [Related]
19. Effect of a new potent CCK antagonist, lorglumide, on caerulein- and bombesin-induced pancreatic secretion and growth in the rat. Scarpignato C; Varga G; Dobronyi I; Papp M Br J Pharmacol; 1989 Mar; 96(3):661-9. PubMed ID: 2470456 [TBL] [Abstract][Full Text] [Related]
20. Fasting prevents acute pancreatitis induced by cerulein in rats. Otsuki M; Tani S; Okabayashi Y; Fujii M; Nakamura T; Fujisawa T; Koide M; Itoh H Dig Dis Sci; 1990 Jul; 35(7):840-8. PubMed ID: 2364838 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]